{"id":604986,"date":"2022-06-22T19:24:02","date_gmt":"2022-06-22T19:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604986"},"modified":"2022-06-22T19:24:02","modified_gmt":"2022-06-22T19:24:02","slug":"cancer-biomarkers-market-growth-demand-company-profiles-and-key-players-strategies-forecast-report-datam-intelligence","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-biomarkers-market-growth-demand-company-profiles-and-key-players-strategies-forecast-report-datam-intelligence_604986.html","title":{"rendered":"Cancer Biomarkers Market Growth Demand Company Profiles and Key Players Strategies Forecast Report | DataM Intelligence"},"content":{"rendered":"
\n
\"Cancer<\/a><\/div>\n
\n
DataM Intelligence | Cancer Biomarkers Market<\/div>\n<\/div>\n<\/div>\n
Some of the key players which are contributing to the growth of the Cancer Biomarkers Market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, and other major companies listed in the final report.<\/div>\n

Cancer Biomarkers Market Growth Drivers Insights:<\/strong><\/p>\n

According to the research study published by the DataM Intelligence, the global Cancer Biomarkers Market<\/a> size is projected to reach USD billion by the end of 2029, with growth at a CAGR of approximately 13.2% during the forecast period 2022-2029.<\/p>\n

Cancer biomarkers are biological molecules secreted either by tumors or from tissues in response to cancer, which are then later used to measure and evaluate the cancer growth processes in the body. Cancer biomarkers are used on or for the patients when undergoing curative cancer treatment; these can be further used to follow up the disease condition at the early stage or for the possible recurrent disease.<\/p>\n

The global cancer biomarkers market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer.<\/p>\n

To know more insights on Market Size, Demand, and Company Profile Analysis, Kindly Download Our Sample Brochure @ https:\/\/www.datamintelligence.com\/download-sample\/cancer-biomarkers-market<\/a><\/p>\n

The presence of potential pipeline candidates is driving the market growth<\/strong><\/p>\n

Many pharmaceutical companies are actively investing in the research and development of novel biomarkers for the diagnosis and treatment of cancer. Many potential candidates are in their end stages of development and are projected to give a tremendous boost to the market after their launch.<\/p>\n

This is limiting the number of patients undergoing biomarker testing, and the growing preference of patients toward other low-cost detection tests.<\/p>\n

Report Statistics:<\/strong><\/p>\n\n\n\n\n\n\n
\n

Metric<\/strong><\/p>\n<\/td>\n

\n

Details<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Market CAGR<\/p>\n<\/td>\n

\n

~13.2%<\/p>\n<\/td>\n<\/tr>\n

\n

Fastest Growing Region<\/p>\n<\/td>\n

\n

Asia Pacific<\/p>\n<\/td>\n<\/tr>\n

\n

Largest Market<\/p>\n<\/td>\n

\n

North America<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cancer Biomarkers Market Segmentation:<\/strong><\/p>\n

By Cancer Indication:<\/strong><\/p>\n

Sarcoma<\/p>\n

Colorectal Cancer<\/p>\n

Cervical Cancer<\/p>\n

Lung Cancer<\/p>\n

Breast Cancer<\/p>\n

By Biomarker Type:<\/strong><\/p>\n

Protein Biomarkers<\/p>\n

Genetic Biomarkers<\/p>\n

Others<\/p>\n

By Profiling Technology:<\/strong><\/p>\n

Omics Technologies<\/p>\n

Cytogenetics<\/p>\n

Immunoassays<\/p>\n

Imaging Technologies<\/p>\n

Bioinformatics<\/p>\n

By Application:<\/strong><\/p>\n

Drug Discovery and Development<\/p>\n

Disease Screening and Diagnosis<\/p>\n

Treatment Planning & Risk Assessment<\/p>\n

Others<\/p>\n

HER-2 segment held the largest share in 2021 due to the rising prevalence of breast cancer and increasing awareness about disease diagnosis in both developed and developing countries.<\/p>\n

Geographical Classification:<\/strong><\/p>\n

North America<\/p>\n

Latin America<\/p>\n

Europe<\/p>\n

Middle East and Africa<\/p>\n

Asia Pacific<\/p>\n

Rest of the world<\/p>\n

Cancer Biomarkers Market Regional Insights:<\/strong><\/p>\n

North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market’s growth can be attributed to the increasing R&D on cancer biomarkers and rising technological advancements in the development of cancer biomarkers. Moreover, the high incidence rate of cancer in the region propels market growth.<\/p>\n

Make an Inquire before purchasing the full report @ https:\/\/www.datamintelligence.com\/enquiry\/cancer-biomarkers-market<\/a><\/p>\n

Major Companies Profiled in the global Cancer Biomarkers Market:<\/strong><\/p>\n

Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Becton, Dickinson and Company, Merck Millipore, Agilent Technologies among others.<\/p>\n

The Full Report has the below insights.<\/strong><\/p>\n

    \n
  1. The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).<\/li>\n
  2. Visualize the composition of the Cancer Biomarkers Market Segmentation By Cancer Indication, By Biomarker Type, By Profiling Technology, By Application, and Region, highlighting the key commercial assets and players.<\/li>\n
  3. Identify commercial opportunities in the Market by analyzing trends and co-development deals.<\/li>\n
  4. The report also covers data insights on various industry forces such as porter’s five forces, regulations in each country, reimbursement scenario, technological advancements, PEST analysis, and pricing analysis.<\/li>\n
  5. Excel data sheet with thousands of Market-level 4\/5 segmentation data points.<\/li>\n
  6. PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. <\/li>\n
  7. Product mapping in excel for the key product of all major market players<\/li>\n
  8. The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages. <\/li>\n<\/ol>\n

    Additional Benefits Post Purchase:<\/strong><\/p>\n

      \n
    1. Unlimited Analyst support for a period of 1 year.<\/li>\n
    2. Any query regarding the scope offered will be addressed within 24- 48 hours.<\/li>\n
    3. An excel sheet with market numbers will be provided separately<\/li>\n<\/ol>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DataM Intelligence<\/a>
      Contact Person:<\/strong> Sai
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> +1 877 441 4866
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.datamintelligence.com\/research-report\/cancer-biomarkers-market<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DataM Intelligence | Cancer Biomarkers Market Some of the key players which are contributing to the growth of the Cancer Biomarkers Market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,411,416],"tags":[],"class_list":["post-604986","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=604986"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=604986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=604986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=604986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}